MARA Holdings
MARA
MicroStrategy
MSTR
Tesla
TSLA
Coinbase
COIN
Amazon
AMZN
US Stock MarketDetailed Quotes
GMAB Genmab
- 21.470
- +0.470+2.24%
Close Jan 3 16:00 ET
- 21.400
- -0.070-0.33%
Post 18:00 ET
13.64BMarket Cap21.56P/E (TTM)
21.560High21.120Low839.05KVolume21.150Open21.000Pre Close17.96MTurnover0.13%Turnover Ratio23.62P/E (Static)635.24MShares32.88052wk High3.10P/B13.49BFloat Cap19.85052wk Low--Dividend TTM628.45MShs Float49.070Historical High--Div YieldTTM2.10%Amplitude16.240Historical Low21.402Avg Price1Lot Size
About Genmab Company
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Company Profile
SymbolGMAB
Company NameGenmab
Listing DateJul 18, 2019
Issue Price17.75
Founded1998
CEODr. Jan G. J. van de Winkel, PhD
MarketNASDAQ
Employees2204
Securities TypeDR
ADS Ratio10.0 : 1.0
Fiscal Year Ends12-31
AddressCarl Jacobsens Vej 30,Valby
CityCopenhagen
ProvinceCentral Denmark
CountryDenmark
Zip Code2500
Phone45-70-20-27-28
Websitehttp://www.genmab.com
Company Executives
- Name
- Position
- Salary
- Dr. Jan G. J. van de Winkel, PhD
- President and Chief Executive Officer
- 44.30M
- Dr. Judith Klimovsky, M.D.
- Executive Vice President and Chief Development Officer
- 21.70M
- Anthony Mancini
- Executive Vice President and Chief Operating Officer
- 21.80M
- Dr. Tahamtan Ahmadi, PhD
- Executive Vice President, Chief Medical Officer and Head of Experimental Medicines
- 19.80M
- Birgitte Stephensen
- Executive Vice President and Chief Legal Officer
- 10.10M
- Anthony Pagano
- Executive Vice President and Chief Financial Officer
- 19.60M
- Dr. Martine J. van Vugt, PhD
- Executive Vice President and Chief Strategy Officer
- 8.90M
- Christopher Cozic
- Executive Vice President and Chief People Officer
- 13.20M
- Dr. Mijke Zachariasse
- Director, Vice President and Head of Antibody Research Materials
- 1.10M
- Pernille Erenbjerg
- Deputy Chairman of the Board
- 2.10M
- Deirdre P. Connelly
- Chairman of the Board
- 2.80M
- Martin Schultz
- Director, Senior Director and Head of Development Business Partnership and Strategy
- 800.00K
- Takahiro Hamatani
- Director and Senior Director, Finance Japan
- 800.00K
- Anders Gersel Pedersen, M.D.,PhD
- Director
- 1.70M
- Elizabeth G. O’Farrell
- Independent Director
- 1.90M
- Rolf Karl-Heinz Hoffmann
- Independent Director
- 1.50M
- Dr. Paolo Paoletti, M.D.
- Independent Director
- 1.50M
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.